Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 09.02.2026 1 Am J Hum Genet 2 Anticancer Res 1 BMC Cancer 3 BMC Urol 2 Cancer 1 Cancer Res 1 Clin Cancer Res 2 Eur Radiol 1 Eur Urol 1 Hum Pathol 1 Int J Radiat Oncol Biol Phys 4 Int J Urol 1 J Natl Cancer Inst 2 J Nucl Med 2 Lancet Oncol 1 Magn Reson Imaging 1 Oncogene 1 Oncol Rep 1 PLoS One 1 Proc Natl Acad Sci U S A 2 Urol Int 5 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hum Genet

1. CHENG S, Suger AH, Goss LB, Zhang J, et al
   Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program.
   Am J Hum Genet. 2026;113:392-398.
   PubMed         Abstract available
   
   

   
   Anticancer Res

2. YAMADA Y, Shirafuji T, Sato K, Tsujino T, et al
   Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy.
   Anticancer Res. 2026;46:1107-1116.
   PubMed         Abstract available
   
   
3. LIU J, Hsu CY, Lu J, Zhang LE, et al
   Prognostic Significance of PPFIA2 in Localized Prostate Cancer: Integrative Analysis and Functional Validation.
   Anticancer Res. 2026;46:757-770.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. AVASTHI KK, Manley BJ, Pellini B, Zhang J, et al
   Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer.
   BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15492.
   PubMed         Abstract available
   
   

   
   BMC Urol

5. XU L, Wang J
   Multimodal management of primary mixed neuroendocrine prostate cancer with bone flare phenomenon: a rare case report and therapeutic insights.
   BMC Urol. 2026 Feb 5. doi: 10.1186/s12894-026-02064.
   PubMed        
   
   
6. BEDIR S, Unal B, Ebiloglu T, Demiral S, et al
   The comparison of post-treatment quality of life after at least two years of follow-up (>/= 24 months) between robotic radical prostatectomy and radiotherapy for intermediate-risk localized prostate cancer.
   BMC Urol. 2026 Feb 5. doi: 10.1186/s12894-025-02018.
   PubMed         Abstract available
   
   
7. ALTAY MS, Kocaturk H, Bedir B, Bedir F, et al
   Impact of positive surgical margin location on biochemical recurrence in pT3 prostate cancer after robot-assisted radical prostatectomy: a retrospective cohort study.
   BMC Urol. 2026 Feb 4. doi: 10.1186/s12894-026-02069.
   PubMed         Abstract available
   
   

   
   Cancer

8. MONTGOMERY B, Lynch JA, Brown J, Maxwell KN, et al
   Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study.
   Cancer. 2026;132:e70283.
   PubMed         Abstract available
   
   
9. LANE BR, Lewicki P, Noyes SL, Labardee C, et al
   Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy.
   Cancer. 2026;132:e70291.
   PubMed         Abstract available
   
   

   
   Cancer Res

10. MONTEAGUDO-GARCIA O, Nombela P, Roman AC, Fernandez-Rodero V, et al
    ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation.
    Cancer Res. 2026;86:622-641.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

11. MUNZUR AD, Herberts C, Kwan EM, Emmett L, et al
    Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
    Clin Cancer Res. 2026 Feb 6. doi: 10.1158/1078-0432.CCR-25-4001.
    PubMed         Abstract available
    
    

    
    Eur Radiol

12. ENGLMAN C, Adebusoye B, Cosenza M, Del Prete A, et al
    Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study.
    Eur Radiol. 2026 Feb 6. doi: 10.1007/s00330-025-12318.
    PubMed         Abstract available
    
    
13. RENARD-PENNA R
    The velocity challenge: MRI reveals highly variable prostate cancer growth rates in active surveillance.
    Eur Radiol. 2026 Feb 6. doi: 10.1007/s00330-025-12312.
    PubMed        
    
    

    
    Eur Urol

14. ARMSTRONG AJ, Petrylak DP, Shore ND, Szmulewitz RZ, et al
    ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Eur Urol. 2026 Feb 2:S0302-2838(25)04876-6. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Hum Pathol

15. LANIPEKUN OK, Wang Y, Miyamoto H
    Clinical significance of the relative location of perineural cancer invasion on prostate biopsy: Detection within 1-mm of the core tip as an independent prognosticator.
    Hum Pathol. 2026;168:106015.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

16. HOWELL JN, Wilkes J, Maughan NM, Patel RB, et al
    Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade.
    Int J Radiat Oncol Biol Phys. 2026;124:575-580.
    PubMed         Abstract available
    
    

    
    Int J Urol

17. UMEMORI M, Urabe F, Iwamoto Y, Imai Y, et al
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70368.
    PubMed         Abstract available
    
    
18. MIURA N, Shimbo M, Shishido K, Nobumori S, et al
    Impact of the 2025 NCCN Definition Change for Very High-Risk Prostate Cancer on Surgical Outcomes After Robot-Assisted Radical Prostatectomy: A Retrospective Cohort.
    Int J Urol. 2026;33:e70366.
    PubMed         Abstract available
    
    
19. SASAKI T, Igarashi A, Ebara S, Tatenuma T, et al
    Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94).
    Int J Urol. 2026;33:e70370.
    PubMed         Abstract available
    
    
20. HATAKEYAMA S, Yoneyama T, Ohyama C
    Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.
    Int J Urol. 2026;33:e70371.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

21. FISCHER MP, Alena M, Braun A, Kraft J, et al
    Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer.
    J Natl Cancer Inst. 2026 Feb 2:djag027. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

22. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [(177)Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270916. doi: 10.2967/jnumed.125.270916.
    PubMed         Abstract available
    
    
23. HARTENBACH M, Rasul S, Grubmuller B, Kramer G, et al
    PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.
    J Nucl Med. 2025 Nov 20:jnumed.125.270404. doi: 10.2967/jnumed.125.270404.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

24. TANG C, Sherry AD, Hwang H, Farris DP, et al
    Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.
    Lancet Oncol. 2026;27:181-190.
    PubMed         Abstract available
    
    
25. SPOHN SKB, Grosu AL
    Oligometastatic prostate cancer: time to integrate metastasis-directed therapy.
    Lancet Oncol. 2026;27:139-141.
    PubMed        
    
    

    
    Magn Reson Imaging

26. ZHANG KS, Glemser PA, Neelsen CJO, Wennmann M, et al
    Repeatability and reproducibility of maximum diameter measurements of prostate lesions on MRI with repositioning and variation of imaging sequences: A test-retest study.
    Magn Reson Imaging. 2025 Nov 27:110578. doi: 10.1016/j.mri.2025.110578.
    PubMed         Abstract available
    
    

    
    Oncogene

27. BROOKE GN, Leach DA, Culley RL, Azadova A, et al
    Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.
    Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03682.
    PubMed         Abstract available
    
    

    
    Oncol Rep

28. SHEN P, Wang X, Yan X, Du H, et al
    High RMI1 expression is associated with cancer cell progression and poor prognosis in prostate cancer.
    Oncol Rep. 2026;55:55.
    PubMed         Abstract available
    
    

    
    PLoS One

29. ZHANG C, Yu J, Ji T, Zhao K, et al
    Loss of IL1RA promotes prostate cancer growth and metastasis by activating Akt signaling pathway.
    PLoS One. 2026;21:e0339611.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

30. TENDLER S, De Gregorio R, Balderes P, Michel AL, et al
    Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.
    Proc Natl Acad Sci U S A. 2026;123:e2505785123.
    PubMed         Abstract available
    
    

    
    Urol Int

31. POLAT H, Sungur U, Eksi M, Guner E, et al
    The Relationship of Chronic Inflammation in Prostate Biopsies with International Society of Urological Pathology Score Upgrade after Radical Prostatectomy.
    Urol Int. 2026;110:55-61.
    PubMed         Abstract available
    
    
32. DONCK E, Fede Spicchiale C, Yang T, Bou Kheir G, et al
    Pelvic lymph node dissection during radical prostatectomy for prostate cancer: harms versus benefits.
    Urol Int. 2026 Feb 2:1-21. doi: 10.1159/000550027.
    PubMed         Abstract available
    
    

    
    Urology

33. SHACHAR E, Connor SE, Chen J, Kwan L, et al
    Authors' Reply to Editorial Comments on, "Fear of Cancer Recurrence among Uninsured and Underrepresented Men with Prostate Cancer".
    Urology. 2026 Jan 29:S0090-4295(26)00071-3. doi: 10.1016/j.urology.2026.
    PubMed        
    
    
34. BILEN MA, Shore N, Burbage S, Rossi C, et al
    Homologous recombination repair mutations, next-generation sequencing testing, and treatment progression by race among patients with metastatic castration-sensitive prostate cancer.
    Urology. 2026 Jan 29:S0090-4295(26)00060-9. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    
35. ASHOURI R, Reynolds PS, Rajavel S, Hanchate K, et al
    Development of a Prognostic Prediction Model for Clinically Significant Prostate Cancer Based on Lesion Zone and Apparent Diffusion Coefficient Value Quantification.
    Urology. 2026 Jan 28:S0090-4295(26)00061-0. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    
36. HANSEN SC, Schlaepfer CH, Shane DM, Erickson BA, et al
    Measuring the Impact of Common Prostate Cancer Survivorship Conditions with Health Utilities.
    Urology. 2026 Jan 29:S0090-4295(26)00062-2. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    
37. PATNAIK S, Maganty A
    Editorial Comment on "Sociodemographic Factors Associated with Tissue-Based Genomic Testing for Prostate Cancer".
    Urology. 2026 Feb 3:S0090-4295(26)00085-3. doi: 10.1016/j.urology.2026.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum